<DOC>
	<DOCNO>NCT00381303</DOCNO>
	<brief_summary>The purpose study evaluate difference effectiveness , safety , tolerability PREZISTA ( darunavir ; DRV ) 600 mg , administer ritonavir ( RTV ) 100 mg twice day virologic response ( defined viral load ( VL ) &lt; 50 copies/mL ) 48-week treatment period HIV-positive woman men . Additional antiretroviral ( ARV ) agent also administer chosen Investigator base resistance test prior treatment history ( refer Optimized Background Regimen ( OBR ) ) .</brief_summary>
	<brief_title>GRACE : A Study Compare Effectiveness , Safety Tolerability PREZISTA ( Darunavir ) /Ritonavir Gender Race When Administered With Other Antiretroviral Medications Human Immunodeficiency Virus ( HIV ) Positive Women Men .</brief_title>
	<detailed_description>This multi-center , open-label ( doctor patient know drug administer ) , Phase IIIb clinical trial evaluate difference effectiveness , safety , tolerability darunavir/ritonavir sex and/or race 48-week treatment period . This study conduct HIV positive woman men treat previously antiretroviral therapy . This study enroll 70 % woman conduct U.S. , Puerto Rico , Mexico Canada approximately 420 patient receive darunavir 600 mg ritonavir 100 mg twice daily . The primary objective study determine percentage patient achieve virologic response , define viral load ( VL ) &lt; 50 copies/mL week 48 . Secondary study objective include comparison endpoint woman men well race across multiple parameter include limited change CD4 count baseline week 48 , time loss virologic response ( TLOVR ) , change metabolic parameter ( blood chemistry ) , etc . Within 4 week Screening Visit ( initial visit investigator determine eligibility ) , Investigator receive data require determine patient 's eligibility construct individual Optimized Background Regimen ( OBR ) use treatment period combination darunavir/ritonavir patient enrol study . The OBR consist additional antiretroviral ( ARV ) agent also administer study choose Investigator base resistance test prior treatment history . The study Sponsor provide follow ARV agent , may use option OBR : TMC 125 ( investigational non-nucleoside reverse transcriptase inhibitor ; NNRTI ) ; Truvada ( tenofovir/emtricitabine ) ; Viread ( tenofovir ) ; Emtriva ( emtricitabine ) ; Zidovudine . Other NRTIs ( nucleoside reverse transcriptase inhibitor ) NNRTIs may use discretion Investigator , provide Sponsor . The Baseline Visit ( Day 1 ) follow 48-week treatment period patient evaluate Weeks 4 , 8 , 12 , 16 , 24 , 36 , 48 final Follow-Up Visit Week 52 . ( total 10 visit Screening final visit ) . At number visit throughout study , blood sample obtain assess defined laboratory value , safety parameter determine concentration study drug darunavir , TMC125 ( applicable ) ritonavir ) . Patients assessed change CD4 count HIV-RNA throughout study . At visit , vital sign assess patient ask untoward medical occurrence record adverse event ( AEs ) and/or HIV-related event . Detailed definition report procedure AEs provide part protocol . Study patient receive PREZISTA ( darunavir ) 600 mg boost 100 mg ritonavir orally ( mouth ) twice day combination antiretroviral drug 48 week .</detailed_description>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>HIV Seropositivity</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Darunavir</mesh_term>
	<criteria>Documented HIV infection Plasma HIVRNA &gt; = 1000 copies/mL Must able comply protocol requirement No prior use PREZISTA ( darunavir ) , TMC125 , enfuvirtide , tipranavir No currently active AIDS defining illness , Category C condition accord Center Disease Control [ CDC ] Classification System HIV Infection ( 1993 ) follow exception , must discuss Sponsor prior enrollment : stable cutaneous Kaposi 's Sarcoma , Wasting syndrome due HIV infection Not currently use investigational drug Not pregnant breastfeed No Grade 3 4 laboratory abnormality define DAIDS ( Division AIDS , National Institute Allergy Infectious Diseases ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>HIV</keyword>
	<keyword>AIDS</keyword>
	<keyword>Immunodeficiency Virus , Human</keyword>
	<keyword>Females</keyword>
	<keyword>Women</keyword>
	<keyword>PREZISTA</keyword>
	<keyword>darunavir</keyword>
	<keyword>TMC114</keyword>
	<keyword>Protease Inhibitor</keyword>
</DOC>